A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya

NCT04826094 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

143

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Env-C Plasmid DNA
BIOLOGICAL: HIV Env gp145 C.6980 protein
DRUG: Rehydragel®
BIOLOGICAL: ALF43
BIOLOGICAL: dmLT
DRUG: Placebo (IM)
DRUG: Placebo (TCl)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]
[object Object]